Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369193 | 0.94 | KCNH2 (0.54) | KCNH2KCNA3PIK3CAMTORPRKDC | |
| SCHEMBL11999871 | 0.83 | KCNA3 (0.48) | KCNH2KCNA3DRD2DRD3ATM | |
| SCHEMBL922760 | 0.82 | KCNH2 (0.58) | KCNH2MCHR1 | |
| SCHEMBL706366 | 0.82 | MTNR1A (0.51) | KCNH2KCNA3PIK3CAMTORPRKDC | |
| SCHEMBL10285563 | 0.81 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL3856834 | 0.80 | KCNH2 (0.64) | KCNH2 | |
| SCHEMBL21197944 | 0.80 | KCNH2 (0.57) | KCNH2KCNA3DRD2 | |
| SCHEMBL13234465 | 0.78 | KCNH2 (0.46) | KCNH2KCNA3PIK3CAMTORPRKDC | |
| SCHEMBL10313824 | 0.78 | KCNA3 (0.47) | KCNH2KCNA3DRD2DRD3ATM | |
| SCHEMBL1422362 | 0.78 | PIK3CA (0.45) | KCNH2PIK3CAMTORPRKDCDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885KCNA3 1771/4885PIK3CA 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.